Diabetic Foot Infection (DFI) – Global Clinical Trials Review, H2, 2021
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
This report provides top-line data relating to the clinical trials on diabetic foot infection (DFI). This report includes an overview of trials count and their average enrollment in top countries conducted globally. Moreover, the report includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status, and sponsor type. It also provides prominent drug names and trial counts for in-progress trials (based on the number of ongoing trials).
The diabetic Foot Infection (DFI) clinical trial report consists of 117 trials. Trials conducted by companies in Phase IV, Phase III, Phase II, and Phase I stand at 7, 12, 12, and 38 respectively. Similarly, the trials with different status compile of completed – 72, ongoing – 15, planned – 10, terminated – 6, and withdrawn – 14. out of 72 completed trials, 42 trials have achieved end point(s). GlobalData’s Clinical Trials Database features trials from across the globe covering more than 20 therapy areas and nearly 2,000 indications.
Which are the top regions and countries in the global diabetic foot infection clinical trials market?
In total there were more than 100 clinical trials conducted on diabetic foot infection, as of December 2021. Out of these the highest clinical trials have been conducted in Europe. In the country-wise analysis, China and the US have the highest number of DFI clinical trials. Spain had the highest average patient enrollment in diabetic foot infection clinical trials.
North America: North America stands at the third position after Asia-Pacific and Europe in terms of the number of clinical trials of diabetic foot infection. In terms of top countries, the US has the highest number of diabetic foot infection clinical trials, followed by Canada and Mexico.
Europe: More than 30 trials have taken place in Europe out of which Russia has the highest number of diabetic foot infection clinical trials, followed by the UK, Austria, Germany, and Spain.
Asia-Pacific: Asia-Pacific stands at the second-highest after Europe as per the number of trials in the global diabetic foot infection clinical trial market. In the Asia-Pacific region, China had the highest number of DFI clinical trials, followed by Australia, India, South Korea, and Taiwan.
Middle East & Africa: The Middle East and Africa come at the fourth position as per the number of trials in the global diabetic foot infection clinical trials market. Iran had the highest number of diabetic foot infection clinical trials, followed by Egypt, South Africa, and Israel.
Central & South America: Central and South America holds the fifth position as per the number of trials in the global diabetic foot infection clinical trial market. Brazil had the highest number of DFI clinical trials, followed by Argentina, Chile, Colombia, and Panama.
G7 Countries: Among the G7 (the US, the UK, Germany, France, Italy, Canada, and Japan) countries, the UK had the highest proportion of diabetic foot infection to metabolic disorders clinical trials as of December 2021. France also had a significant proportion of diabetic foot infections to metabolic disorders clinical trials followed by Italy, the US, Germany, and Canada.
E7 Countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Russia had the highest proportion of diabetic foot infection to metabolic disorders clinical trials, followed by China, Turkey, India, Brazil, Mexico, and Indonesia.
Global diabetic foot infection clinical trials market, by region
For more regional insights, download a free report sample
What are the key phases in the global diabetic foot infection clinical trials market?
There were over 30 clinical trials in Phase I, of which two clinical trials were in progress for the time period 1995-2021. Out of 72 completed trials, more than 40 clinical trials have reached end points. The maximum number of clinical trials in progress are in phase II.
Which are the key sponsors in the global diabetic foot infection clinical trials market?
Merck & Co Inc, TaiGen Biopharmaceuticals Holdings Lt, Innocoll Holdings Ltd, Teva Pharmaceutical Industries Ltd, Tissuetech, Advanced Pharma, Dipexium Pharmaceuticals Inc (Inactive), Hetero Drugs Ltd, ICON Plc, and Pfizer Inc are the key sponsors in the global DFI clinical trials market.
Global diabetic foot infection clinical trials market, by key sponsors
For more key sponsor insights, download a free report sample
Market report scope
Key regions | Europe, Asia-Pacific, Middle East & Africa, North America, and Central & South America |
Key countries | The US, Russia, the UK, China, Australia, India, Iran, Austria, Germany, and Spain |
Key sponsors | Merck & Co Inc, TaiGen Biopharmaceuticals Holdings Lt, Innocoll Holdings Ltd, Teva Pharmaceutical Industries Ltd, Tissuetech, Advanced Pharma, Dipexium Pharmaceuticals Inc (Inactive), Hetero Drugs Ltd, ICON Plc, and Pfizer Inc |
Scope
- The report provides a snapshot of the global clinical trials landscape.
- Report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and end point status.
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company.
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with the reason for unaccomplishment.
- The report provides enrollment trends for the past five years.
- The report provides the latest news for the past three months.
Reasons to Buy
- Assists in formulating key business strategies with regard to investment.
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
- Provides top-level analysis of the global clinical trials market which helps in identifying key business opportunities.
- Supports understanding of trials count and enrollment trends by country in the global therapeutics market.
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
- Facilitates clinical trial assessment of the indication on a global, regional, and country-level.
TaiGen Biopharmaceuticals Holdings Ltd
Innocoll Holdings Ltd
Teva Pharmaceutical Industries Ltd
Tissuetech Inc
Advanced Pharma
Dipexium Pharmaceuticals Inc (Inactive)
Hetero Drugs Ltd
ICON Plc
Pfizer Inc
Table of Contents
Table
Figures
Frequently asked questions
-
Which are the key regions in the global diabetic foot infection clinical trials market?
The key regions in the DFI clinical trials market are Europe, North America, Asia-Pacific, the Middle East and Africa, and South and Central America.
-
Which are the key countries in the global diabetic foot infection clinical trials market?
The key countries in the global DFI clinical trials market are the US, Russia, the UK, China, Australia, India, Iran, Austria, Germany, and Spain
-
Which are the key sponsors in the global diabetic foot infection clinical trials market?
Merck & Co Inc, TaiGen Biopharmaceuticals Holdings Lt, Innocoll Holdings Ltd, Teva Pharmaceutical Industries Ltd, Tissuetech, Advanced Pharma, Dipexium Pharmaceuticals Inc (Inactive), Hetero Drugs Ltd, ICON Plc, and Pfizer Inc are the key sponsors in the global DFI clinical trials market.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Metabolic Disorders reportsDiabetic Foot Infection (DFI) – Global Clinical Trials Review, H1, 2021
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
GlobalData's clinical trial report, “Diabetic Foot Infection (DFI) – Global Clinical Trials Review, H1, 2021" provides an overview of Diabetic Foot Infection (DFI) Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Foot Infection (DFI). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma – Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
– The report provides a snapshot of the global clinical trials landscape
– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
– The Report provides enrollment trends for the past five years
– Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to Buy
– Assists in formulating key business strategies with regards to investment
– Helps in identifying prominent locations for conducting clinical trials which saves time and cost
– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
– Supports understanding of trials count and enrollment trends by country in global therapeutics market
– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
– Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
TaiGen Biopharmaceuticals Holdings Ltd
Innocoll Holdings Ltd
Tissuetech Inc
Advanced Pharma
Dipexium Pharmaceuticals Inc (Inactive)
Hetero Drugs Ltd
Pfizer Inc
PRA Health Sciences Inc
Teva Pharmaceutical Industries Ltd
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.